WANY
SMMT icon

Wealthspire Advisors (New York)’s Summit Therapeutics SMMT Stock Holding History

Wealthspire Advisors (New York)’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10
Closed -$207 – 2596
2025
Q3 		$207 Buy
+10
New +$243 ﹤0.01% 2937

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.16B AUM 135.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Wealthspire Advisors (New York)'s SMMT Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 10 shares — an estimated $207 sold.

Wealthspire Advisors (New York) first reported a position in SMMT in Q3 2025 and held it in 1 quarter. The position peaked at $207 in Q3 2025. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 10 Summit Therapeutics shares in Q4 2025, an estimated $207.
  • Wealthspire Advisors (New York) first reported a position in Summit Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Summit Therapeutics position peaked at $207 in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.